# Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis

> **NCT01029847** · PHASE4 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 49 (actual)

## Conditions studied

- Spondyloarthritis

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01029847
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01029847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01029847, "Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01029847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*